Starpharma (ASX: SPL) has announced that it will present at the Bio-Europe conference in Munich this week.
The company will also be conducting partnering discussions for VivaGel BV and DEP with pharmaceutical companies.
Bio-Europe is Europe’s largest partnering conference for biotechnology and life sciences companies, attracting more than 4,000 attendees representing more than 1,800 companies.
Starpharma’s VP Business Development, Dr Tony Eglezos, will present in the Enabling Technologies conference stream, with the presentation focusing on Starpharma’s DEP drug delivery platform.
Areas covered will include:
- DEP docetaxel which is currently in the clinic;
- The recent AstraZeneca license deal; and,
- Recent positive results of studies utilising targeted DEP conjugates in an ovarian cancer model.
The licensing agreement with AstraZeneca could deliver the company over half a billion dollars.
The agreement covers the development and commercialisation by AstraZeneca of compounds directed at a defined family of targets using Starpharma’s DEP drug delivery technology.
This week's presentation includes new data on targeted DEP conjugates where Starpharma’s technology significantly outperformed both Trastuzumab and Trastuzumab emtansine in an ovarian cancer model.
Targeted therapies for cancer such as antibody drug conjugates combine targeting antibodies with conventional drugs to improve their performance. An example is Roche’s Trastuzumab emtansine, more commonly known as KADCYLA.
“Targeted products are of substantial interest within the pharmaceutical industry in the search for new and improved therapies. Data from Starpharma’s recent targeted DEP studies are proving to be of significant interest to partners and attendees of the conference.” said Dr Tony Eglezos, VP Business Development.